Genzyme Says Work At Allston Plant Will Resume As Planned Later This Month
This article was originally published in The Pink Sheet Daily
Executive Summary
Viral contamination in one of the plant's bioreactors caused a complete shutdown, stopping new production of Cerezyme and Fabrazyme.
You may also be interested in...
Next-Generation Sequencing For Adventitious Virus Detection Helps Speed Response To COVID-19
It's another case where the pandemic spurs adoption of ways to speed the manufacture of vaccines and biologics that have been in development for years.
WHO Proposes Reference Standard For Adventitious Virus Detection
Emerging global standard could speed testing of biologics and gene therapies for stray viral particles, while sparing laboratory animals.
Continued Genzyme Problems Offer Gaucher Opportunity To Competitors
Genzyme's Allston Landing, Mass., plant - currently the only facility that produces its Cerezyme and Fabrazyme drugs - resumed working at full capacity on Aug. 28. But it seems the big biotech's manu-facturing woes are far from over: a mid-August visit by the European Medicines Agency found deficiencies, and a critical FDA inspection is still to come